VarmX is a biotech company focused on developing VMX-C001, a universal bypassing agent designed to restore blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants (FXa-DOACs). Their innovative approach aims to stop severe bleeding and mitigate bleeding risks during surgeries for these patients. Founded by Professor Pieter Reitsma, a leading expert in Hemostasis and Thrombosis, VarmX is backed by a strong syndicate of investors and is positioned to make a significant impact in the coagulation therapy market.
Something looks off?